miR-29c regulates resistance to paclitaxel in nasopharyngeal cancer by targeting ITGB1.
Exp Cell Res
; 378(1): 1-10, 2019 05 01.
Article
em En
| MEDLINE
| ID: mdl-30779921
ABSTRACT
Paclitaxel (Taxol) is an anticancer taxane drug commonly used in the treatment of nasopharyngeal carcinoma (NPC). However, resistance to paclitaxel is a major difficulty in developing an effective therapy against NPC. MicroRNAs (miRNAs) are known to regulate genes that are involved in drug resistance. We assessed the effects of miR-29c, an miRNA identified in a genome-wide study of Taxol resistance, on genes associated with resistance in NPC cells. We established Taxol resistance in two human NPC cell lines, SUNE-1 and C666-1 (SUNE-1-Taxol and C666-1-Taxol) and found that miR-29c was downregulated and integrin beta-1 (ITGB1) was upregulated in Taxol-resistant NPC cells compared with parental NPC cells. Further investigations using a TUNEL assay and BAX/BCL-2 ratio, found that overexpression of miR-29c and knockdown of ITGB1 can resensitize drug-resistant NPC cells to Taxol and promote apoptosis. In addition, a dual-luciferase reporter assay indicated that ITGB1 is the target of miR-29c. Furthermore, silencing miR-29c markedly increased Taxol-resistant NPC tumor growth in a nude mouse xenograft model while knockdown of ITGB1 reversed this result. Overall, these data demonstrate that miR-29c regulates resistance to Taxol in NPC by targeting ITGB1. Our research indicates that miR-29c may have potential use in Taxol-resistant NPC therapy.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Nasofaríngeas
/
Paclitaxel
/
Resistencia a Medicamentos Antineoplásicos
/
Integrina beta1
/
MicroRNAs
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Revista:
Exp Cell Res
Ano de publicação:
2019
Tipo de documento:
Article